Evidence map›Paper›PMID 35121890›Full record

ArticleNature cancer2021

Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity.

Shelley E Ackerman, Cecelia I Pearson, Joshua D Gregorio, Joseph C Gonzalez, Justin A Kenkel, Felix J Hartmann, Angela Luo, Po Y Ho, Heidi LeBlanc, Lisa K Blum and 23 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 195 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors at 4 institutions in 2 countries.

Shelley E AckermanDepartment of Bioengineering, Stanford University Schools of Medicine and Engineering, Stanford, CA, USA.
Cecelia I PearsonBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Joshua D GregorioBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Joseph C GonzalezBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Justin A KenkelBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Felix J HartmannDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-4174-2276
Angela LuoBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Po Y HoBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Heidi LeBlancBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Lisa K BlumBolt Biotherapeutics, Inc., Redwood City, CA, USA.ORCID http://orcid.org/0000-0002-7921-8939
Samuel C KimmeyDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5742-4037
Andrew LuoBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Murray L NguyenBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Jason C PaikDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Lauren Y SheuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2038-9909
Benjamin AckermanDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Arthur LeeBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Hai LiBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Jennifer MelroseBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Richard P LauraBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Vishnu C RamaniBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Karla A HenningBolt Biotherapeutics, Inc., Redwood City, CA, USA.ORCID http://orcid.org/0000-0002-1099-6089
David Y JacksonBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Brian S SafinaBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Grant YonehiroBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Bruce H DevensBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Yaron CarmiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-0972-0616
Steven J ChapinBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Sean C BendallDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1341-2453
Marcin KowanetzBolt Biotherapeutics, Inc., Redwood City, CA, USA.
David DornanBolt Biotherapeutics, Inc., Redwood City, CA, USA.
Edgar G EnglemanDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Michael N AlonsoBolt Biotherapeutics, Inc., Redwood City, CA, USA. malonso@boltbio.com.ORCID http://orcid.org/0000-0003-3859-7669
Stanford University · USJohns Hopkins University · USStanford Medicine · USTel Aviv University · IL

Funding

Supplement to Enhance Wellness and Resiliency in the Graduate EnvironmentT32GM007276 · NIGMS · STANFORD UNIVERSITY · PI MORRISON, ASHBY J. · 1985 to 2023
$32.9M
Spatial-Genomic Integrative Multi-Species Analysis of Lymph Node MetastasisU54CA209971 · NCI · STANFORD UNIVERSITY · PI NOLAN, GARRY P, PLEVRITIS, SYLVIA KATINA · 2016 to 2021
$11.0M
Targeting Dectin-2 on Tumor-associated Macrophages for the Treatment of CancerR01CA222969 · NCI · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G. · 2018 to 2022
$2.1M
NCI NIH HHS R01 CA222969NCI NIH HHS U54 CA209971NIGMS NIH HHS T32 GM007276
6 · The paper itself

Abstract

Innate pattern recognition receptor agonists, including Toll-like receptors (TLRs), alter the tumor microenvironment and prime adaptive antitumor immunity. However, TLR agonists present toxicities associated with widespread immune activation after systemic administration. To design a TLR-based therapeutic suitable for systemic delivery and capable of safely eliciting tumor-targeted responses, we developed immune-stimulating antibody conjugates (ISACs) comprising a TLR7/8 dual agonist conjugated to tumor-targeting antibodies. Systemically administered human epidermal growth factor receptor 2 (HER2)-targeted ISACs were well tolerated and triggered a localized immune response in the tumor microenvironment that resulted in tumor clearance and immunological memory. Mechanistically, ISACs required tumor antigen recognition, Fcγ-receptor-dependent phagocytosis and TLR-mediated activation to drive tumor killing by myeloid cells and subsequent T-cell-mediated antitumor immunity. ISAC-mediated immunological memory was not limited to the HER2 ISAC target antigen since ISAC-treated mice were protected from rechallenge with the HER2

Indexed as

ImmunotherapyNeoplasmsAdaptive ImmunityAnimalsAntigens, NeoplasmMiceTumor MicroenvironmentAntigens, Neoplasm

Identifiers

PMID35121890
PMCPMC9012298
OpenAlexW3111948793

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.